# Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines

> **NCT05970887** · PHASE4 · COMPLETED · sponsor: **Catholic Kwandong University** · enrollment: 154 (actual)

## Conditions studied

- Immune Response
- Safety

## Interventions

- **BIOLOGICAL:** bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
- **BIOLOGICAL:** quadrivalent influenza vaccine

## Key facts

- **NCT ID:** NCT05970887
- **Lead sponsor:** Catholic Kwandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-12
- **Primary completion:** 2022-12-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2024-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970887, "Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05970887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*